secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K/A
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001193125-23-270796
Event type: m_and_a
Sentiment:  negative
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus files Surface Oncology audited financials: $63.6M net loss in 2022, going concern noted
--------------------------------------------------------------------------------

- Surface Oncology reported net loss of $63.6M for 2022 on $30M revenue; accumulated deficit reached $204.3M.
- Auditor raised substantial doubt about Surface's ability to continue as a going concern due to operating losses, debt repayment, and lease termination.
- For 2020, Surface had net income of $59.3M and revenue of $126.2M from GSK license, but losses resumed thereafter.
- Pro forma combined financial statements as of June 30, 2023 reflect the merger with Coherus, completed September 8, 2023.
- Surface paused internal clinical development of SRF617 and reduced workforce by ~20% in Q4 2022, incurring $4M restructuring charge.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000119312523270796/0001193125-23-270796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000119312523270796/d574677d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-270796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer